This site is intended for U.S. healthcare professionals only.

Ordering HepaGam B®

Ordering HepaGam B®

NDC numbers for HepaGam B®

Product Description

NDC Code




(>312 IU/mL) - Carton

1 mL carton


(>312 IU/mL) - Carton

5 mL carton

Specific J code for reimbursement

Reimbursement Codes


Code Description


HepaGam B® INTRAVENOUS injection


HepaGam B® INTRAMUSCULAR injection

These codes are specific to HepaGam B® and should not be used for any other HBIg unless otherwise directed by your payer.

For more information, please contact the customer service line at 1-877-HepaGam B (437-2426).

How do I order HepaGam B®?

Please contact your specialty distributor to order product. For all other questions, please call 1-877-HepaGam B (437-2426).

How is HepaGam B® stored?

HepaGam B® is stored at 36 to 46° F (2 to 8° C). Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration; if these are seen, vials should not be used. During preparation, do not shake vials; avoid foaming. Use HepaGam B® within six hours after the vial has been entered. Do not reuse or save for future use. This product contains no preservative; therefore, partially used vials should be discarded immediately due to the risk of contamination.

Can you freeze HepaGam B®?

Do not freeze.


Indications and Important Safety Information for HepaGam B®


HepaGam B® [Hepatitis B Immune Globulin Intravenous (Human)] is an intravenous immune globulin indicated for the following:

  • Prevention of Hepatitis B recurrence following liver transplant in HBsAg-positive liver transplant patients

  • Post-exposure prophylaxis including:

    • Acute exposure to HBsAg-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc.),
    • Perinatal exposure of infants born to HBsAg-positive mothers,
    • Sexual exposure to HBsAg-positive persons, and
    • Household exposure to persons with acute HBV infection.

Important Safety Information

CONTRAINDICATIONS: Individuals known to have severe, potentially life-threatening reaction to human globulin preparations should not receive HepaGam B® or any other immune globulin (human). Individuals who are deficient in IgA may have the potential to develop IgA antibodies and have severe, potentially life-threatening allergic reactions.

For post-exposure prophylaxis indications, HepaGam B® must be administered intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, HepaGam B® should be given only if the expected benefits outweigh the potential risks.

WARNINGS and PRECAUTIONS: HepaGam B® [Hepatitis B Immune Globulin Intravenous (Human)] is a sterile solution of gamma globulin (IgG) made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jacob disease (CJD) agent.

Thrombotic events have been reported in association with the use of immune globulins. Patients at risk include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, coagulation disorders, prolonged periods of immobilization, and/or known/suspected hyperviscosity.

The maltose contained in HepaGam B® can interfere with some types of blood glucose monitoring systems. Only testing systems that are glucose-specific should be used in patients receiving HepaGam B®. This interference can result in falsely elevated glucose readings that can lead to untreated hypoglycemia or to inappropriate insulin administration, resulting in life-threatening hypoglycemia.

Liver transplant patients should be monitored regularly for serum anti-HBs antibody levels.

Certain adverse drug reactions may be related to the rate of infusion. The recommended infusion rate must be closely followed. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period and immediately following an infusion.

The most common adverse drug reactions observed in clinical trial subjects were hypotension and nausea (2% of clinical trial subjects).

For product inquiries about HepaGam B®, call (877) 437-2426.

Please see full Prescribing Information for full prescribing details.